Pasquale F Innominato1, David Spiegel2, Ayhan Ulusakarya3, Sylvie Giacchetti4, Georg A Bjarnason5, Francis Lévi6, Oxana Palesh2. 1. Assistance Publique - Hôpitaux de Paris, Department of Oncology, Paul Brousse Hospital, Villejuif, France; INSERM, UMRS 776 'Rythmes Biologiques et Cancers', Villejuif, France. Electronic address: pasquale.innominato@inserm.fr. 2. Center for Stress and Health, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford, CA, USA. 3. Assistance Publique - Hôpitaux de Paris, Department of Oncology, Paul Brousse Hospital, Villejuif, France; INSERM, UMRS 776 'Rythmes Biologiques et Cancers', Villejuif, France. 4. INSERM, UMRS 776 'Rythmes Biologiques et Cancers', Villejuif, France; Breast Diseases Unit, Department of Medical Oncology, Assistance Publique - Hôpitaux de Paris, St. Louis Hospital, Paris, France. 5. Division of Medical Oncology, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada. 6. Assistance Publique - Hôpitaux de Paris, Department of Oncology, Paul Brousse Hospital, Villejuif, France; INSERM, UMRS 776 'Rythmes Biologiques et Cancers', Villejuif, France; Université Paris Sud 11, UMR-S0776, Orsay, France; Cancer Chronotherapy Unit, Warwick Medical School, Warwick University, Coventry, Warwickshire, UK.
Abstract
BACKROUND: Sleep disorders are prevalent in patients with advanced cancer. Their impact on clinical outcomes is not well understood. METHODS: A post-hoc analysis was conducted in 361 chemo-naïve patients with metastatic colorectal cancer completing twice the EORTC QLQ-C30 questionnaire within a randomized international phase III trial. The study assessed the effect on overall survival (OS) of subjective sleep complaint, used as a normal or a time-dependent covariate (TDC), using a multivariate Cox proportional hazard model. Prognostic analysis was conducted on the whole study population and separately in each treatment arm (conventional FOLFOX2, or chronomodulated chronoFLO4). RESULTS: Sleep problems were reported by 202 patients (56%) at baseline and by 188 (52%) on treatment. Sleep problems at baseline were independently associated with a higher risk of earlier death (HR: 1.36; p = 0.011), progression (HR: 1.43; p = 0.002) and poor treatment response (RR: 0.58; p = 0.016). TDC analysis confirmed the independent prognostic effect of sleep problems on OS (HR: 1.37; p = 0.008), while on treatment this effect was only observed using univariate analysis. The negative prognostic value of sleep problems on OS at baseline, on treatment, and as a TDC was greatest on chronoFLO4 compared to FOLFOX2. CONCLUSIONS: Subjective sleep problems are associated with poor clinical outcomes in metastatic colorectal cancer patients and affect chronotherapy effectiveness. There is a need for a well-tuned circadian timing system in order to increase chronotherapy activity. Prospective studies are needed for determining the impact of therapeutic approaches on sleep disorders upon quality of life and survival of cancer patients.
BACKROUND: Sleep disorders are prevalent in patients with advanced cancer. Their impact on clinical outcomes is not well understood. METHODS: A post-hoc analysis was conducted in 361 chemo-naïve patients with metastatic colorectal cancer completing twice the EORTC QLQ-C30 questionnaire within a randomized international phase III trial. The study assessed the effect on overall survival (OS) of subjective sleep complaint, used as a normal or a time-dependent covariate (TDC), using a multivariate Cox proportional hazard model. Prognostic analysis was conducted on the whole study population and separately in each treatment arm (conventional FOLFOX2, or chronomodulated chronoFLO4). RESULTS: Sleep problems were reported by 202 patients (56%) at baseline and by 188 (52%) on treatment. Sleep problems at baseline were independently associated with a higher risk of earlier death (HR: 1.36; p = 0.011), progression (HR: 1.43; p = 0.002) and poor treatment response (RR: 0.58; p = 0.016). TDC analysis confirmed the independent prognostic effect of sleep problems on OS (HR: 1.37; p = 0.008), while on treatment this effect was only observed using univariate analysis. The negative prognostic value of sleep problems on OS at baseline, on treatment, and as a TDC was greatest on chronoFLO4 compared to FOLFOX2. CONCLUSIONS: Subjective sleep problems are associated with poor clinical outcomes in metastatic colorectal cancer patients and affect chronotherapy effectiveness. There is a need for a well-tuned circadian timing system in order to increase chronotherapy activity. Prospective studies are needed for determining the impact of therapeutic approaches on sleep disorders upon quality of life and survival of cancer patients.
Authors: C Calderon; A Carmona-Bayonas; R Hernandez; B Castelo; S Varma; O Donnay; D Gomez; P Jimenez-Fonseca Journal: Clin Transl Oncol Date: 2019-02-02 Impact factor: 3.405
Authors: Oxana Palesh; Karyn Haitz; Francis Lévi; Georg A Bjarnason; Carl Deguzman; Igbal Alizeh; Ayhan Ulusakarya; Mary Melissa Packer; Pasquale F Innominato Journal: Qual Life Res Date: 2017-06-27 Impact factor: 4.147
Authors: Annabelle Ballesta; Pasquale F Innominato; Robert Dallmann; David A Rand; Francis A Lévi Journal: Pharmacol Rev Date: 2017-04 Impact factor: 25.468
Authors: Brian D Gonzalez; Sarah L Eisel; Bo Qin; Adana A M Llanos; Josée Savard; Aasha I Hoogland; Heather Jim; Yong Lin; Kitaw Demissie; Chi-Chen Hong; Elisa V Bandera Journal: Support Care Cancer Date: 2020-09-29 Impact factor: 3.603
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Marilyn J Hammer; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022 Mar-Apr 01 Impact factor: 2.592